Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027969 · ClinicalTrials.gov registry record · Phase 4
Metabolic Surgery for Atrial Fibrillation Elimination
A Phase 4 study, sponsored by Ali Aminian.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07027969: Clinical Trial Phase 4 study, sponsored by Ali Aminian.
NCT07027969 is a Phase 4 study that has not yet begun recruiting, run by Ali Aminian. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07027969, a Phase 4 study, has not yet begun recruiting, sponsored by Ali Aminian.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Primary Outcome
Relative change from baseline to 52 weeks in the percentage total duration of being in AF during a 2-week monitoring period (i.e., %burden), assessed by the Zio XT Patch (iRhythm).
Interventions
- PROCEDURE Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- DRUG Anti-Obesity Medication (AOM) treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-11-01 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
What is known before NCT07027969 opens enrollment
NCT07027969 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Roux-en-Y Gastric Bypass or Sleeve Gastrectomy is the first listed.
NCT07027969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07027969 about?
NCT07027969 is a clinical study titled "Metabolic Surgery for Atrial Fibrillation Elimination". Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension...
What is the current status of trial NCT07027969?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-11-01. Estimated completion is 2030-03-31.
What interventions are being tested in trial NCT07027969?
The interventions under investigation include: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy (PROCEDURE), Anti-Obesity Medication (AOM) treatment (DRUG).
Who is sponsoring clinical trial NCT07027969?
This trial is sponsored by Ali Aminian, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07027969's enrollment target sits among peer trials
100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI